Camel IgG ELISA Kit (DEIASL056)

Regulatory status: For research use only, not for use in diagnostic procedures.

Write a review

Serum, plasma
Species Reactivity
Intended Use
The test kit can be used for measurement of total IgG in camel serum.
The test kit will remain stable for six months from the date of purchase provided that the components are stored at 2-8°C. The microtiter plate should be kept in a sealed bag with desiccant to minimize exposure to damp air.
General Description
Three major IgG isotypes are found in camel: IgG1, IgG2, and IgG3. IgG1 resembles IgG from other species in that it is comprised of two heavy chains and two light chains. IgG2 and IgG3 each consist of two heavy chains but both lack light chains. The heavy chains of IgG2 and IgG3 lack the CH1 domain present in IgG1. The hinge region between the CH2 and VH domain is longer in IgG2, giving it a slightly higher molecular weight.
Reconstitution And Storage
1x Immunoglobulin Diluent: The diluent is provided as a 10x stock. Prior to use, estimate the final volume of diluent required for your assay and dilute one (1) volume of the 10x stock with nine (9) volumes of distilled or deionized water.
1x Wash Solution: The wash solution is provided as a 20x stock. Prior to use, dilute the contents of the bottle (50 mL) with 950 mL of distilled or deionized water.


Have you cited DEIASL056 in a publication? Let us know and earn a reward for your research.

Related Products

Customer Reviews

Write a review, share your experiences with others and get rewarded !
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket
Product Name Cat. No. Applications Host Species Datasheet Price Add to Basket


Seropositivity of measles antibodies in the Israeli population prior to the nationwide 2018-2019 outbreak


Authors: Bassal, Ravit; Indenbaum, Victoria; Pando, Rakefet; Levin, Tal; Shinar, Eilat; Amichay, Doron; Barak, Mira; Ben-Dor, Anat; Haim, Adina Bar; Mendelson, Ella; Cohen, Dani; Shohat, Tamy

Measles vaccine is administered in Israel as part of the routine childhood immunization program, at ages 1 and 6 years. In this study, we assessed seropositivity of the Israeli population against measles before the onset and propagation of the 2018-2019 measles outbreak. From the Israel Center for Disease Control National Serum Bank, 3,164 samples collected during 2015 were tested for measles antibodies. All the tests were performed using Enzyme-Linked Immunosorbent Assay (ELISA) commercial kit (Enzygnost, Anti-Measles Virus/IgG: Behring, Marburg, Germany). The overall seropositivity rate for measles was 90.7%. The seropositivity rate at 6 months and younger was 48.9%, and decreased to 3.8% among infants aged 6-11 months. Seropositivity increased to 90.7% in the 1-4-year age group, and reached 96.1% for 5-9 year-old children. Our results suggest high immunity in the Israeli population against measles virus, but not high enough to prevent outbreaks because of pockets of specific population groups with low immunization coverage. Infants between ages 6 and 11 months and children younger than 2 years had the lowest seropositivity rates being the age groups with the highest attack rates of measles during the epidemic of 2018. Efforts should be aimed at avoiding any delay in vaccination once a child reaches the age of 1 year and improving immunity levels in children aged 1-4 years.

Performance of an automated chemiluminescence SARS-CoV-2 IG-G assay


Authors: Lau, C. S.; Oh, H. M. L.; Hoo, S. P.; Liang, Y. L.; Phua, S. K.; Aw, T. C.

Introduction: We describe our evaluation of the Abbott SARS-CoV-2 IgG assay on the Architect immunoassay analyser. Methods: We assessed assay precision, sensitivity, specificity, positive/negative predictive values (PPV/NPV), cross-reactivity (influenza/dengue/hepatitis B and C/rheumatoid factor/anti-nuclear/double-stranded DNA/syphilis) and sample throughput in samples from real-time polymerase chain reaction (RT-PCR) positive patients/healthcare workers (HCWs)/pre-pandemic samples. We compared the cut-off indexes (COIs) between all control samples (HCWs and pre-pandemic) to generate an optimised COI limit for reactivity. Results: The assay specificity was 99.8% (n = 980) and sensitivity was 45.9-96.7% (n = 279). When tested >= 14 days post-positive RT-PCR (POS), the PPV/NPV was 96.4%/99.8%. The difference between the COIs of HCWs/pre-pandemic samples was small (0.01, p < 0.0001). There was minimal cross-reactivity with other antibodies. A lower COI limit for reactivity (>= 0.55, using the 99th percentile COI of our controls and ROC analysis) improved diagnostic sensitivity, especially at 0-6 days POS (45.9-55.8%), with a small decrease in specificity (98.9%). The assay throughput was 100 samples in 70 min. Conclusion: The Abbott SARS-CoV-2 IgG assay shows excellent performance in patients >= 14 days POS. The difference between the COIs of HCWs and pre-pandemic samples was numerically small. A lower COI limit improves assay sensitivity with a slight decrease in specificity.

Online Inquiry

Phone: *
E-mail Address: *
Technology Interest:
Type of Organization:
Service & Products Interested: *
Project Description:
Verification code
Click image to refresh the verification code.

Online Inquiry

  Interested in larger quantities ? request a quote!
  Protocol may be improved. Please feel free to contact us to obtain the latest version.!

Ordering Information

Payment methods we support:
Invoice / Purchase Order
Credit card

OUR PROMISE TO YOU Guaranteed product quality expert customer support

Inquiry Basket